Interní Med. 2014; 16(4): 134-140

Phenotypically oriented therapy in patients with COPD

MUDr.Vladimír Koblížek, Ph.D.
Plicní klinika FN a ,LF UK Hradec Králové

COPD is heterogeneous syndrome. Vast majority of symptomatic COPD subjects (B and D GOLD categories) has expressed a specific phenotype or combination of phenotypes. Current guidelines in Spain and in the Czech Republic include instructions relating to diagnostic and therapeutic approach to COPD phenotypes. This article contains a brief summary of the elementary theses of the Czech COPD recommendations.

Keywords: COPD, management, phenotypes, GOLD, guidelines

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koblížek V. Phenotypically oriented therapy in patients with COPD. Interní Med. 2014;16(4):134-140.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagno- sis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. 2013 Feb [cited 2013 Nov 2]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Re- port_2013_ Feb20.pdf.
    2. Koblížek V, a kol. CHOPN. Doporučený postup ČPFS pro diagnostiku a léčbu chronické obstrukční plicní nemoci. Praha: Maxdorf, 2013: 134.
    3. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J, 2005; 26: 948-968. Go to original source... Go to PubMed...
    4. Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. BMJ, 2006; 332: 1142. Go to original source... Go to PubMed...
    5. Gershon A, Warner L, Cascagnette P, et al. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet, 2011; 378: 991-996. Go to original source... Go to PubMed...
    6. Malý M, Zvolský M, Rozborilova E, et al. Respiratory Mortality in Czech and Slovak Republics in the year 2011. Stud Pneumol Phtiseol, 2013; 73: 128-132.
    7. Halbert R, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest, 2003; 123: 1684-1692. Go to original source... Go to PubMed...
    8. Buist A, Mc Burnie M, Vollmer W, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 2007; 370: 741-750. Go to original source... Go to PubMed...
    9. Topalovic M, Exadaktylos V, Peeters A, et al. Computer quantification of airway collapse on forced expiration to predict the presence of emphysema. Resp Res, 2013; 14: 131. Go to original source... Go to PubMed...
    10. Lanjewar S, Chhabra L, Chaubey V, et al. Diagnostic electrocardiographic dyad criteria of emphysema in left ventricular hypertrophy. Int J COPD, 2013; 8: 591-594. Go to original source...
    11. Celli B. Update on the management of COPD. Chest, 2008; 133: 1451-1462. Go to original source... Go to PubMed...
    12. Miravitles M, Calle M, Soler-Cataluna J. Clinical phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bronch, 2012; 48: 86-98. Go to original source... Go to PubMed...
    13. Price D, Small M, Milligan G, et al. Impact of night-time symptoms in COPD: a real-world study in five European countrie. Int J COPD, 2013; 8: 595-603. Go to original source... Go to PubMed...
    14. Bakke P, Ronmark E, Eagan T, et al. Recommendations for epidemiological studies on COPD. Eur Respir J, 2011; 38: 1261-1277. Go to original source... Go to PubMed...
    15. Lanken P, Terry P, DeLisser H, et al. An Official American thoracic society clinical policy statement - Palliative care for patients with respirátory disease and critical illnesses. Am J Respir Crit Care, 2008; 177: 912-927. Go to original source... Go to PubMed...
    16. Strassman R, Bausch B, Spaar A, et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J, 2009; 34: 634-640. Go to original source... Go to PubMed...
    17. Qaseem A, Wilt T, Weinberger S, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update for the ACP, ACCP, ATS and ERS. Ann Intern Med, 2011; 155: 179-191. Go to original source... Go to PubMed...
    18. Neumannová K, Zatloukal J, Jakubec P, et al. Kombinace neinvazivní ventilační podpory a rehabilitační léčby u pacientů s chronickou obstrukční plicní nemocí. Studia pneumologica et phtiseologica, 2013; 73: 23-28.
    19. Divo M, Cote C, de Torres J, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2012; 186: 155-161. Go to original source... Go to PubMed...
    20. Miravitles M, Soler-Cataluna J, Calle M, et al. Spanish COPD Guidelines. Treatment of stable COPD. Arch Bronch, 2012; 48: 247-257. Go to original source... Go to PubMed...
    21. Lischke R, Schutzner J, Stolz A, et al. Lung transplantation-present status worldwide and in the Czech Republic. Cas Lek Cesk, 2003; 142: 712-716. Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.